0 123

Cited 0 times in

Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

DC Field Value Language
dc.date.accessioned2023-06-02T01:11:16Z-
dc.date.available2023-06-02T01:11:16Z-
dc.date.issued2022-04-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194712-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleRisk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJ. Trigo-
dc.contributor.googleauthorB.C. Cho-
dc.contributor.googleauthorK. Park-
dc.contributor.googleauthorN. Girard-
dc.contributor.googleauthorS. Viteri-
dc.contributor.googleauthorP. Garrido-
dc.contributor.googleauthorM.G. Krebs-
dc.contributor.googleauthorM. Thayu-
dc.contributor.googleauthorR.E. Knoblauch-
dc.contributor.googleauthorJ. Xie-
dc.contributor.googleauthorJ.M. Bauml-
dc.contributor.googleauthorR.W. Schnepp-
dc.contributor.googleauthorA. Londhe-
dc.contributor.googleauthorP. Mahadevia-
dc.contributor.googleauthorN. Leighl -
dc.identifier.doi10.1016/j.annonc.2022.02.029-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0923753422001454-
dc.citation.volume33-
dc.citation.numbersuppl 2-
dc.citation.startPageS38-
dc.citation.endPageS39-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.33(suppl 2) : S38-S39, 2022-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.